Intravenous Dofetilide, a Class III Antiarrhythmic Agent, for the Termination of Sustained Atrial Fibrillation or Flutter

Abstract

Intravenous dofetilide can convert sustained atrial fibrillation or flutter to sinus rhythm. However, its efficacy is greater in flutter--a response that contrasts with the poorer response seen with class I agents. This finding potentially represents an important advance in the pharmacologic termination of atrial flutter.

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

“…Poza Europą jest dostępny dofetilid, który może przerwać AF o niedawnym początku [606]. Kardiowersja farmakologiczna przywraca rytm zatokowy u ok. 50% pacjentów z AF o niedawnym począt-ku (tab.…”

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

“…597 -605 Outside of Europe, dofetilide is available and can convert recent-onset AF. 606 Pharmacological cardioversion restores sinus rhythm in approximately 50% of patients with recent-onset AF (Table 16). 607 -609 In the short-term, electrical cardioversion restores sinus rhythm quicker and more effectively than pharmacological cardioversion and is associated with shorter hospitalization.…”

Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter

“…У больных с ФП продолжительностью от 2 ч до 6 мес препарат восстанавливал СР у 22,2% больных с ФП и у 67% с ТП. Дофетилид дозозависимо удлинял ин-тервал Q-T/Q-Tc и приводил к развитию полиморфной ЖТ в 6-8,3% случаев [25].…”